Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.

[1]  T. Wiemken,et al.  Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot Study , 2016, Lung.

[2]  D. Shasha,et al.  Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. , 2015, International journal of antimicrobial agents.

[3]  W. Boersma,et al.  Antibiotic treatment strategies for community-acquired pneumonia in adults. , 2015, The New England journal of medicine.

[4]  Bing Li,et al.  β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.

[5]  T. Wiemken,et al.  Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia , 2014, Inflammation.

[6]  T. Marrie,et al.  Macrolides and Mortality in Critically Ill Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis* , 2014, Critical care medicine.

[7]  M. M. van der Eerden,et al.  Single versus combination antibiotic therapy in adults hospitalised with community-acquired pneumonia , 2013, Thorax.

[8]  L. Leibovici,et al.  Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  B. Henriques Normark,et al.  Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia , 2013, Thorax.

[10]  W. Lim,et al.  Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia , 2012, Thorax.

[11]  T. Marrie,et al.  Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Ramirez,et al.  Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. , 2009, Archives of internal medicine.

[13]  R. Wunderink,et al.  Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia , 2009, European Respiratory Journal.

[14]  A. Ma,et al.  Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. , 2007, Chest.

[15]  T. Marrie,et al.  Addition of a macrolide to a ß-lactam in bacteremic pneumococcal pneumonia , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[16]  A. Anzueto,et al.  The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia , 2005, Critical care.

[17]  L. Leibovici,et al.  Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. , 2005, Archives of internal medicine.

[18]  R. Fisher,et al.  American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. , 2004, Gastroenterology.

[19]  G. Zou,et al.  A modified poisson regression approach to prospective studies with binary data. , 2004, American journal of epidemiology.

[20]  F. Fraschini,et al.  Effect of Multiple Doses of Clarithromycin and Amoxicillin on IL-6, IFNγ and IL-10 Plasma Levels in Patients with Community Acquired Pneumonia , 2004, Journal of chemotherapy.

[21]  P. Gross,et al.  Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. , 2003, Chest.

[22]  Á. Soriano,et al.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. Wunderink,et al.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. , 2001, Archives of internal medicine.

[24]  J. Van Damme,et al.  Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. , 2000, The Journal of antimicrobial chemotherapy.

[25]  H. Ceri,et al.  Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. , 2000, The Journal of antimicrobial chemotherapy.

[26]  G W Sun,et al.  Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. , 1996, Journal of clinical epidemiology.

[27]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.